Our Research

The Southern Consortium Node has participated in over 36 research projects in the CTN. See a listing of all of the CTN protocols

Current/recently completed projects include:

CTN0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Disorder. This study was conducted at Behavioral Health Services of Pickens County, and the site PI was Susan Sonne, PharmD.  This study is complete.

CTN0089: Integrating Nurse Practitioner Buprenorphine Waiver Training into Graduate Nursing Curriculum. This project was led by Carolyn Bogdon, MSN,FNP-BC, and Karen Hartwell, MD. This training project is complete. 

CTN0099: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED INNOVATION). MUSC/SCN is actively participating in this study; Lindsay Jennings, MD is the site PI. Recruitment is expected to end in Spring of 2024.

CTN0107: Peer Recovery Support:  A Bridge to Treatment for Overdose Survivors. The study is being led by the SCN; Kelly Barth, DO is the Lead Investigator, and Erin McClure, PhD, is the National Project Director. The recruitment goal was successfully met, and the sites are now in active followup.

CTN0107-A-1: Why Do Patients Decline Buprenorphine from the Emergency Department? This is an add-on study to CTN0107, involving interviews with patients offered buprenorphine in the ED, as well as buprenorphine prescribers in peers working in the ED. Angie Moreland, PhD and Lindsey Jennings, MD are co-leading this multi-site project. Recruitment is ongoing.

CTN0108: Transcranial Magnetic Stimulation for the Treatment of Cocaine/Methamphetamine Use Disorder. This study is being co-led by the SCN and the Texas Node, and is currently recruiting. Recruitment is slated to end in December, 2023.

CTN0109: Randomized, PlaceboControlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2). Dr. Peter Hendricks at UAB is the site PI for this study; It is actively enrolling.

CTN0121: Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders (SUD) among Hospitalized Patients. Ellen Eaton, MD at UAB is the site PI for this study; recruitment is slated to start in Fall of 2023.